Drug Trial Radar · NCT00934492
Cotrimoxazole Prophylaxis in Severely Malnourished Children
Last checked: Nov 19, 2026Latest source record: Aug 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,781
Actual
Start
Nov 2009
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kenya Medical Research Institute
- First posted
- Jul 8, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 months, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial aims to test the hypothesis that mortality among Kenyan children with severe malnutrition following initial stabilisation is due to ongoing vulnerability to infectious disease, and that long term daily co-trimoxazole prophylaxis will reduce mortality. The objective is to conduct a randomized, double blind, placebo-controlled trial of cotrimoxazole prophylaxis for 6 months among HIV-uninfected children with severe malnutrition following stabilization. The primary outcome will be survival at one year. Secondary outcomes are toxicity, growth, the frequency and causes of hospitalisation and microbial resistance to antibiotics. Cotrimoxazole has striking protective efficacy against mortality among children with HIV, despite not altering the underlying immune deficiency. It is hypothesised that co-trimoxazole prophylaxis will have a similar effect in children immunocompromised because of severe malnutrition. Worldwide, severe malnutrition is commoner than HIV in childhood and co-trimoxazole is cheap and widely available, making it easily translatable to policy.
Conditions
- Nutrition Disorders
- Life-threatening Infection
Interventions
Cotrimoxazole dispersible tabletDrug
Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
Placebo dispersible tabletDrug
Placebo dispersible tablets 120/240mg daily for six consecutive months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Mbagathi District Hospital
Nairobi, Kenya
KEMRI/Wellcome Trust Research Programme
Kilifi, Coast, Kenya
Malindi District Hospital
Malindi, Coast, Kenya
Coast Provincial General Hospital
Mombasa, Coast, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.